ClinicalTrials.gg
CompletedNCT01133522Updated Nov 2, 2018Results posted

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

A Phase 1 interventional study of Evolocumab and Placebo in Hyperlipidemia, sponsored by Amgen. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-02.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
17th of 21
60 · median 307
Started
2010
the only one that year
Phase 1
2 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 17th largest by enrollment, is the only one that started in 2010, is one of 2 in phase 1, and was the 1st registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

The purpose of the study is to evaluate the safety and tolerability of multiple doses of evolocumab when given as an add-on to stable statin therapy.

Read the detailed description

Participants receiving low-to-moderate-dose statins were randomized in a 1:3 ratio to receive subcutaneous placebo or evolocumab and enrolled sequentially into one of 5 dose-escalation cohorts:

  1. Evolocumab 14 mg/placebo once weekly (QW) × 6 doses
  2. Evolocumab 35 mg/placebo once weekly (QW) × 6 doses
  3. Evolocumab 140 mg/placebo every 2 weeks (Q2W) × 3 doses
  4. Evolocumab 280 mg/placebo every 2 weeks (Q2W) × 3 doses
  5. Evolocumab 420 mg/placebo every 4 weeks (Q2W) × 2 doses.

Participants receiving high-dose statins were randomized 1:3 to receive subcutaneous placebo or evolocumab 140 mg every 2 weeks × 3 doses (Cohort 6).

Participants diagnosed with familial hypercholesterolemia (HeFH) were randomized 1:2 to receive subcutaneous placebo or evolocumab 140 mg every 2 weeks × 3 doses (Cohort 7).

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • AMG145
  • Multiple Dose
  • Statin
  • Ascending
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ages 18 to 70 years (inclusive) at the time of screening with hyperlipidemia
  • (BMI) ≥18 and ≤ 35 kg/m\^2 at the time of screening
  • Low-density lipoprotein cholesterol (LDL-C) level of 70-220 mg/dL (inclusive) at screening as measured by direct assay
  • For Cohorts 1-5: On a stable dose of rosuvastatin (Crestor) \< 40 mg/day, atorvastatin (Lipitor) \< 80 mg/day, or simvastatin (Zocor) 20-80 mg/day for ≥ 1 month prior to enrollment and expected to remain on this dose for the remainder of the study
  • For Cohort 6: On a stable dose of rosuvastatin (Crestor) 40 mg/day or atorvastatin (Lipitor) 80 mg/day for ≥ 1 month prior to enrollment and expected to remain on this dose for the remainder of the study
  • For Cohort 7: Diagnosis of heterozygous familial hypercholesterolemia, based on a score of ≥ 9 points using the World health Organization (WHO) criteria

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of homozygous familial hypercholesterolemia
  • History of heart failure, coronary artery bypass graft, or cardiac arrhythmia
  • History of acute coronary syndrome (e.g. myocardial infarction, hospitalization for unstable angina) or percutaneous coronary intervention, within 12 months prior to enrollment
  • Planned cardiac surgery or revascularization
  • Known aortic, peripheral vascular or cerebrovascular disease (including history of stroke or )
  • Diabetes mellitus with any of the following:

    1. known microvascular or macrovascular disease
    2. > 8.0% at screening
    3. use of any hypoglycemic medication other than metformin
  • Uncontrolled hypertension (systolic blood pressure ≥ 150 or diastolic blood pressure ≥ 90 mmHg) either on or off therapy at screening or at baseline
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.

    Biological: Evolocumab

  • Placebo comparator
    Placebo

    Participants received matching placebo dose regimens by subcutaneous injection.

    Biological: Placebo

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • BiologicalPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    The relationship of each adverse event to the investigational product was assessed by the investigator. A serious adverse event (SAE) is defined as an adverse event that * is fatal * is life threatening (places the subject at immediate risk of death) * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard.

    Time frame: From the first dose of study drug until Day 85

  2. Number of Participants With Anti-Evolocumab Antibodies

    Serum samples were analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-evolocumab binding antibodies. Positive samples were subsequently tested in a receptor-ligand binding bioassay for anti-evolocumab neutralizing antibodies

    Time frame: From the first dose of study drug until Day 85

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Evolocumab

    Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 800 ng/mL.

    Time frame: Day 1, predose and Days 4, 8, 15, 22, 29, 36, 40, 43, 50, 57, 64, 71, 78, and 85

  2. Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab

    Area under the unbound evolocumab serum concentration-time curve from time of last dose to time of last quantifiable concentration following the last dose of evolocumab.

    Time frame: Day 29 predose (last dose for Cohorts 3-7) and Days 36 (predose for Cohorts 1 and 2), 40, 43, 50, 57, 64, 71, 78, and 85

  3. Percent Change From Baseline to End of the Dosing Interval in LDL-C

    Time frame: Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group

  4. Percent Change From Baseline to End of the Dosing Interval in PCSK9

    Serum PCSK9 concentrations were determined by using a qualified enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 15 ng/mL.

    Time frame: Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group

07

Results

Posted Oct 22, 2015

Participant flow

This study enrolled hypercholesterolemic adults receiving stable statin therapy (7 cohorts: 5 on low-to-moderate-dose statins, 1 on high-dose statin therapy, and 1 with heterozygous familial hypercholesterolemia (HeFH) (score ≥9, World Health Organization criteria). First patient enrolled 28 June 2010. Last patient enrolled 24 June 2011.

Participant flow — Overall Study
MilestonePlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3
Started10767762924
Received treatment10666662924
Completed10666662924
Not completed0101100000
Withdrew: Withdrawal by subject0101000000
Withdrew: Physician decision0000100000

Outcome measures

PrimaryNumber of Participants With Adverse Events

The relationship of each adverse event to the investigational product was assessed by the investigator. A serious adverse event (SAE) is defined as an adverse event that * is fatal * is life threatening (places the subject at immediate risk of death) * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard.

Time frame:
From the first dose of study drug until Day 85
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3
Any adverse event7254631711
Treatment-related adverse events1101601200
Serious adverse events0000000000
Discontinuations due to adverse events0000000000
Deaths on study0000000000
SecondaryMaximum Observed Plasma Concentration (Cmax) of Evolocumab

Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 800 ng/mL.

Time frame:
Day 1, predose and Days 4, 8, 15, 22, 29, 36, 40, 43, 50, 57, 64, 71, 78, and 85
Reported as:
Mean · μg/mL
Maximum Observed Plasma Concentration (Cmax) of Evolocumab
μg/mLEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - Evolocumab 140 mg Q2W × 3
Maximum Observed Plasma Concentration (Cmax) of Evolocumab——20.3 ± 13.262.8 ± 22.763.6 ± 11.216.3 ± 10.814.7 ± 2.9
PrimaryNumber of Participants With Anti-Evolocumab Antibodies

Serum samples were analyzed by an electrochemiluminescence (ECL)-based immunoassay for anti-evolocumab binding antibodies. Positive samples were subsequently tested in a receptor-ligand binding bioassay for anti-evolocumab neutralizing antibodies

Time frame:
From the first dose of study drug until Day 85
Reported as:
Number · participants
Number of Participants With Anti-Evolocumab Antibodies
participantsPlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3
Binding Antibodies0001000000
Neutralizing Antibodies0000000000
SecondaryArea Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab

Area under the unbound evolocumab serum concentration-time curve from time of last dose to time of last quantifiable concentration following the last dose of evolocumab.

Time frame:
Day 29 predose (last dose for Cohorts 3-7) and Days 36 (predose for Cohorts 1 and 2), 40, 43, 50, 57, 64, 71, 78, and 85
Reported as:
Mean · day*μg/mL
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab
day*μg/mLEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - Evolocumab 140 mg Q2W × 3
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab——226 ± 2491200 ± 634903 ± 280181 ± 157165 ± 69
SecondaryPercent Change From Baseline to End of the Dosing Interval in LDL-C
Time frame:
Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group
Reported as:
Mean · percent change
Percent Change From Baseline to End of the Dosing Interval in LDL-C
percent changePlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3
Percent Change From Baseline to End of the Dosing Interval in LDL-C3.14 ± 33.73-23.79 ± 21.57-51.76 ± 18.29-69.58 ± 18.13-74.65 ± 3.47-62.01 ± 11.43-3.01 ± 3.09-61.82 ± 17.67-4.89 ± 0.82-62.91 ± 16.04
SecondaryPercent Change From Baseline to End of the Dosing Interval in PCSK9

Serum PCSK9 concentrations were determined by using a qualified enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 15 ng/mL.

Time frame:
Baseline and Day 43 for QW and Q2W groups or Day 57 for Q4W group
Reported as:
Mean · percent change
Percent Change From Baseline to End of the Dosing Interval in PCSK9
percent changePlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3
Percent Change From Baseline to End of the Dosing Interval in PCSK96.00 ± 25.49-42.07 ± 16.99-64.46 ± 3.70-70.42 ± 16.05-91.49 ± 6.45-32.72 ± 29.4143.60 ± 51.39-62.50 ± 18.3336.76 ± 12.54-68.52 ± 10.67

Adverse events

Collected over From the first dose of study drug until Day 85. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/10 (0%)7/10 (70%)
Evolocumab 14 mg QW × 6—0/6 (0%)2/6 (33.3%)
Evolocumab 35 mg QW × 6—0/6 (0%)5/6 (83.3%)
Evolocumab 140 mg Q2W × 3—0/6 (0%)4/6 (66.7%)
Evolocumab 280 mg Q2W × 3—0/6 (0%)6/6 (100%)
Evolocumab 420 mg Q4W × 2—0/6 (0%)3/6 (50%)
High Dose Statin - Placebo—0/2 (0%)1/2 (50%)
High Dose Statin - Evolocumab 140 mg Q2W × 3—0/9 (0%)7/9 (77.8%)
HeFH - Placebo—0/2 (0%)1/2 (50%)
HeFH - Evolocumab 140 mg Q2W × 3—0/4 (0%)1/4 (25%)
Most frequent other events
Showing 10 of 62
Most frequent other events
EventPlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3
Abdominal pain lowerGastrointestinal disorders0/100/60/60/60/60/61/20/90/20/4
Injection site painGeneral disorders0/100/60/60/61/60/61/20/90/20/4
Urinary tract infectionInfections and infestations0/100/61/60/60/60/61/20/90/20/4
Neck massMusculoskeletal and connective tissue disorders0/100/60/60/60/60/61/20/90/20/4
Sinus congestionRespiratory, thoracic and mediastinal disorders0/100/60/60/60/60/60/20/91/20/4
Varicose veinVascular disorders0/100/60/60/60/60/61/20/90/20/4
ConstipationGastrointestinal disorders0/100/60/62/60/60/60/20/90/20/4
Upper respiratory tract infectionInfections and infestations0/100/60/60/62/60/60/20/90/20/4
DiarrhoeaGastrointestinal disorders0/100/61/60/60/60/60/20/90/21/4
Injection site haematomaGeneral disorders2/100/60/60/61/60/60/21/90/20/4

Baseline characteristics

Safety analysis set (all participants who received at least 1 dose of study drug).

Age, Continuous
Age, Continuous(years)PlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3Total
Mean55.8 ± 7.561.3 ± 4.063.7 ± 6.356.2 ± 7.356.3 ± 8.653.8 ± 4.962.0 ± 1.458.2 ± 7.654.5 ± 10.645.0 ± 15.156.9 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3Total
Female641343131026
Male425323161431
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3Total
White or Caucasian966463272247
Black or African American00000000022
Hispanic or Latino10010302007
Asian00010000001
Japanese00000000000
American Indian or Alaska Native00000000000
Native Hawaiian or Other Pacific Islander00000000000
Aborigine00000000000
Low-Density Lipoprotein Cholesterol (LDL-C) Concentration
Low-Density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL)PlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3Total
Mean108.9 ± 21.9126.7 ± 22.1106.5 ± 29.4113.7 ± 14.5105.8 ± 17.0120.3 ± 33.099.0 ± 31.1100.2 ± 25.5168.5 ± 57.3134.5 ± 31.1114.1 ± 27.8
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration(ng/mL)PlaceboEvolocumab 14 mg QW × 6Evolocumab 35 mg QW × 6Evolocumab 140 mg Q2W × 3Evolocumab 280 mg Q2W × 3Evolocumab 420 mg Q4W × 2High Dose Statin - PlaceboHigh Dose Statin - Evolocumab 140 mg Q2W × 3HeFH - PlaceboHeFH - Evolocumab 140 mg Q2W × 3Total
Mean429.0 ± 93.1491.2 ± 157.9399.8 ± 116.7384.8 ± 88.0373.7 ± 96.0459.0 ± 163.4382.5 ± 82.7486.6 ± 214.0478.5 ± 94.0396.0 ± 86.4432.0 ± 133.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012 Nov 6;60(19):1888-98. doi: 10.1016/j.jacc.2012.08.986. Epub 2012 Oct 17. PubMed 23083772 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Sep 2011, 15 months.

Results were first posted in Oct 2015, 4 years 1 month after primary completion.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 15 months is above that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2010
First posted
May 31, 2010
StartActual
Jun 1, 2010
Primary completionActual
Sep 14, 2011
CompletionActual
Sep 14, 2011
Results first posted
Oct 22, 2015
Last update
Nov 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01133522
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 31, 2010
Start date
Jun 1, 2010
Primary completion
Sep 14, 2011
Completion
Sep 14, 2011
Results posted
Oct 22, 2015
Last update
Nov 2, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion